Primary source: Advisory Committee Guidance Documents
Introduction of guidelines encouraging QSP modeling for MABEL dose selection in first-in-human clinical trials, replacing reliance on traditional animal toxicity data.
This guidance aims to improve early-stage safety assessment, reducing the risk of over-exposure and enhancing participant safety in clinical trials, thus impacting pharmacovigilance strategies for early clinical development.
Stakeholders must prepare for discussions about the integration of QSP methods in investigational new drug (IND) submissions, including a review of IND data packages to align with the new recommendations.
Regulatory Intelligence Lead
Review before 2026-10-06.
Introduction of QSP-based modeling for MABEL dose selection; emphasis on human-relevant biological data over traditional animal toxicity for starting dose justification; recommendations for IND submission data packages.
The guidance enhances early-stage safety assessment by providing a robust framework for dose selection in FIH trials, which is critical for preventing over-exposure and managing safety risks in human participants. It encourages the use of human-relevant biological modeling (QSP) to justify safety margins, impacting the pharmacovigilance planning for early clinical development.
Stakeholders must prepare for discussions about the integration of QSP methods in investigational new drug (IND) submissions, including a review of IND data packages to align with the new recommendations.
The FDA has issued draft guidance recommending the use of quantitative systems pharmacology (QSP) models for selecting starting doses in first-in-human trials. This approach emphasizes the importance of human-relevant biological data over traditional animal studies in determining minimum anticipated biological effect levels (MABEL). The guidance is designed to enhance safety assessments and provide a structured framework for regulatory submissions.
What changed: Introduction of guidelines encouraging QSP modeling for MABEL dose selection in first-in-human clinical trials, replacing reliance on traditional animal toxicity data.
Why it matters: This guidance aims to improve early-stage safety assessment, reducing the risk of over-exposure and enhancing participant safety in clinical trials, thus impacting pharmacovigilance strategies for early clinical development.
Practical implication: Stakeholders must prepare for discussions about the integration of QSP methods in investigational new drug (IND) submissions, including a review of IND data packages to align with the new recommendations.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
